Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Interest Expense
Cost of servicing the company's debt during the period.
Avanos Medical, Inc.NYSE: AVNS
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $1.5M fell 28.6% year over year, ahead of the -35.7% change in trailing-twelve-month interest expense. Sequentially, it fell 21.1% from the prior quarter. Over 3 fiscal years it compounded at -26.3% a year.
Context
- Interest expense amounted to 0.6% of revenue in FY2025, down 1.2 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -28.6% holds above the trailing-twelve-month pace of -35.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 4M USD
- Year-over-year change
- -67.2%
- 4-year CAGR
- +4.9%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4M | -67.2% |
| FY2024 | 2024-12-31 | 12.2M | -18.7% |
| FY2023 | 2023-12-31 | 15M | +50.0% |
| FY2022 | 2022-12-31 | 10M | +203.0% |
| FY2021 | 2021-12-31 | 3.3M | — |
Interest Expense vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 interest expense of $7.2M is the 4th highest of the 11 companies compared; the peer median is $2.3M.
- Its year-over-year change of -35.7% is the 5th highest of 9, against a peer median of -42.7%.
- Interest expense amounts to 1.0% of revenue for AVNS, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $864M | -0.5% | +0.5% | 4.0% | |
| LTM Apr 2026 | $42.1M | +23.8% | -4.7% | 4.9% | |
| LTM Mar 2026 | $23.3M | -35.2% | +30.1% | 4.0% | |
| LTM Mar 2026 | $7.2M | -35.7% | -26.3% | 1.0% | |
| LTM Mar 2026 | $3.48M | -70.0% | -22.1% | 2.2% | |
| LTM Mar 2026 | $2.71M | — | +208.9% | 6.7% | |
| LTM Mar 2026 | $1.9M | +248.3% | -43.1% | 0.9% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $985K | -50.3% | +5.6% | 1.0% |
| LTM Mar 2026 | $203K | -78.9% | -60.5% | 0.3% | |
| LTM Mar 2026 | $24K | -97.2% | -81.8% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AVNS) | $2.3M | -42.7% | -4.7% | 1.6% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M |
| Cost of Revenue | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M |
| Gross Profit | 379.9M | 394.2M | 379.7M | 381.3M | 349M |
| Gross Margin | 51.0% | 57.6% | 56.4% | 55.4% | 49.8% |
| Research & Development | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M |
| Selling, General & Admin | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M |
| Operating Expenses | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M |
| Depreciation & Amortization | 38.3M | 41.1M | 43.5M | 45.5M | 29M |
| EBITDA | 48.9M | 77.8M | 50.6M | (345.6M) | (33.2M) |
| EBITDA Margin | 6.6% | 11.4% | 7.5% | -50.2% | -4.7% |
| Operating Income | 86.8M | 41.9M | 65M | 40M | (61.6M) |
| Operating Margin | 11.7% | 6.1% | 9.7% | 5.8% | -8.8% |
| Interest Income | 200K | 1.2M | 2.9M | 5.1M | 3.2M |
| Interest Expense | 3.3M | 10M | 15M | 12.2M | 4M |
| Other Income / Expenses | (79.5M) | (15.2M) | (72.9M) | (443.3M) | (4.6M) |
| Income Before Tax | 7.3M | 26.7M | (7.9M) | (403.3M) | (66.2M) |
| Pre-Tax Margin | 1.0% | 3.9% | -1.2% | -58.6% | -9.4% |
| Income Tax Expense | 1M | 5.2M | 2M | (17M) | 1.7M |
| Net Income | 6.3M | 50.5M | (61.8M) | (392.1M) | (67.9M) |
| Net Margin | 0.8% | 7.4% | -9.2% | -57.0% | -9.7% |
| EPS (Basic) | 0.13 | 1.08 | (1.33) | (8.53) | (1.46) |
| EPS (Diluted) | 0.13 | 1.07 | (1.33) | (8.53) | (1.46) |
| Weighted Avg Shares | 48.1M | 46.9M | 46.6M | 46M | 46.4M |
| Weighted Avg Shares (Diluted) | 48.6M | 47.3M | 46.6M | 46M | 46.4M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.